Institute of Health and Biomedical Innovation

CORRECTION: Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 11, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, University, CDC, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Nursing home, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

The findings were published on October 10, 2023, in the New England Journal of Medicine.

Key Points: 
  • The findings were published on October 10, 2023, in the New England Journal of Medicine.
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • “Nursing Home Decolonization for Infection and Hospitalization Prevention” published in the New England Journal of Medicine on October 10, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2215254?query=featured_home

Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New English Journal of Medicine

Retrieved on: 
Tuesday, October 10, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, CDC, University, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

“The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.

Key Points: 
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • Each year, 3 million healthcare-associated infections (HAIs) such as methicillin-resistant Staphylococcus aureus (MRSA), bloodstream and urinary tract infections occur in U.S. nursing homes.
  • The findings add to a growing body of Dr. Miller’s research that has been funded by NIH, AHRQ, and other federal sources.

Terasaki Institute Welcomes New Members to Leadership Board

Retrieved on: 
Tuesday, August 1, 2023
Institute of Health and Biomedical Innovation, Non-U.S. operators of the M60 Patton, Research, Organization, Machine learning, AI, Female, Defense Innovation Board, Management, Costain

LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI), is pleased to welcome six new members to its Leadership Board.

Key Points: 
  • LOS ANGELES, Aug. 1, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI), is pleased to welcome six new members to its Leadership Board.
  • The TIBI Leadership Board is comprised of distinguished individuals who will utilize their expertise to promote key initiatives and to provide valuable guidance on research and innovation strategies.
  • The new members are as follows:
    Kian Beyzavi – Kian will also be a part of TIBI's Innovation Board, working closely with Leadership Board Chairperson, Dr. Nazli Azimi, and the management team.
  • "We enthusiastically welcome the newest members of our Leadership Board, and will truly benefit from their experience and expertise," said Ali Khademhosseini, Ph.D, TIBI's Director and CEO.

Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy

Retrieved on: 
Tuesday, July 18, 2023
National Center for Advancing Translational Sciences, Institute of Health and Biomedical Innovation, Bronchopulmonary dysplasia, Disease, BPD, Marketing, SBIR, Biotechnology, National Heart, Lung, and Blood Institute, NCATS, Vitamin A, Research, Lung, National Institutes of Health, Bangladesh Technical Education Board, Infant, NHLBI, Division, Risk, Small Business Innovation Research, Orphan, Mortality, UCLA, Therapy, Harbor–UCLA Medical Center, NIH, Neonatal intensive care unit, Family, David Geffen School of Medicine at UCLA, Pharmaceutical industry, EU, Pediatrics, Neonatology, Medicine

DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

Key Points: 
  • DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.
  • This grant allows the Company to position its novel aerosolized vitamin A formulation for commercialization in 2025 to prevent Bronchopulmonary Dysplasia (BPD).
  • With this grant, the Company has now received in excess of $6 million from NIH for its neonatal programs.
  • Dr. Virender continued, “I am extremely pleased to be involved in developing Advent’s novel form of inhalable vitamin A therapy.

Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

Retrieved on: 
Tuesday, July 18, 2023
Institute of Health and Biomedical Innovation, ASP, Nicotine, American Society of Pharmacognosy, MD, Annual general meeting, Smoking, Society, Small business, Conference, Management

SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held at the Bethesda North Marriott Hotel Conference Center in Rockville, MD from July 22-26, 2023.

Key Points: 
  • SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held at the Bethesda North Marriott Hotel Conference Center in Rockville, MD from July 22-26, 2023.
  • Achieve management, John Bencich, Chief Executive Officer, and Richard Stewart, Executive Chairman of the Board of Directors, will present on a public/private partnerships panel titled “SEEDing Biomedical Innovation: Support for Small Businesses at National Institute of Health” to be held on Monday, July 24, 2023, at 10:30 AM EDT.
  • For additional information on the 2023 ASP Annual Meeting, including registration details, please visit the meeting website .

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

Retrieved on: 
Tuesday, July 18, 2023
Microneedle drug delivery, Cognition, Psilocybin, Male, Rat, DMT, Institute of Health and Biomedical Innovation, Shareholder, CSE, Social, Anxiety, CAD, Skin, Cancer, Infection, LSD, Patient, Investment, IND, MDMA, Female, Vaccine, Birth control, Pharmaceutical industry

Both structural aspects and ex-vivo skin insertion assessments of the drug conjugated microneedles have demonstrated successful fabrication and acceptable performance.

Key Points: 
  • Both structural aspects and ex-vivo skin insertion assessments of the drug conjugated microneedles have demonstrated successful fabrication and acceptable performance.
  • The Company will invest three hundred thousand dollars (CAD 300,000) in Sairiyo Therapeutics Inc. (“Sairiyo”), a subsidiary of PharmaDrug Inc., for forty-nine (49%) ownership.
  • The investment allocated to Sairiyo will be used to advance developments of cepharanthine and DMT PharmaPatch™.
  • In connection with the investment, PharmaDrug and PharmaTher (the “Shareholders”) will enter into a unanimous shareholders agreement with respect to their holdings of Sairiyo.

Terasaki Institute Holds Grand Opening Celebration at New Research Center

Retrieved on: 
Friday, May 5, 2023
Linda, The Morning News, Institute of Health and Biomedical Innovation, Education, Terasaki, Research, Doctor of Philosophy, Golden Joystick Awards, Los Angeles City Council District 5, City, KTLA, Laboratory, Organ transplantation, Faculty, Growth, Capitol, Management, Interior design

WOODLAND HILLS, Calif., May 5, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit research organization devoted to developing bioengineered systems, devices, and technology for biomedical applications, held a Grand Opening celebration at their newest research facility in Woodland Hills.

Key Points: 
  • WOODLAND HILLS, Calif., May 5, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI), a non-profit research organization devoted to developing bioengineered systems, devices, and technology for biomedical applications, held a Grand Opening celebration at their newest research facility in Woodland Hills.
  • In addition, a flag that once flew over the United States Capitol in 2018 was presented to the institute from District 32's Congressman Brad Sherman.
  • When combined with TIBI's administrative and research and development buildings in Westwood and West Los Angeles, the institute grows to almost 100,000 square feet of space.
  • "I'm very excited about the addition of the new building to the Terasaki Institute.

Terasaki Institute To Celebrate Grand Opening of Woodland Hills Research Center with Ribbon-Cutting

Retrieved on: 
Thursday, April 27, 2023
Institute of Health and Biomedical Innovation, Next (2020 TV series), National Science Foundation, Research, Biomedical engineering, Bangladesh Technical Education Board, Organ transplantation, Tissue engineering, Greater Los Angeles, Sport, Faculty, Ecosystem, Health, Fitness, Memory, Medical device, Pharmaceutical industry

WOODLAND HILLS, Calif., April 27, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation, a nonprofit dedicated to rapidly translating scientific knowledge into real-world solutions, will celebrate the grand opening of its latest biomedical research center with a ribbon-cutting ceremony on Saturday, April 29.

Key Points: 
  • WOODLAND HILLS, Calif., April 27, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation , a nonprofit dedicated to rapidly translating scientific knowledge into real-world solutions, will celebrate the grand opening of its latest biomedical research center with a ribbon-cutting ceremony on Saturday, April 29.
  • The Terasaki Institute is committed to pushing the boundaries of biomedical engineering research to develop innovative solutions that will transform the future of healthcare," said Terasaki Institute CEO Dr. Ali Khademhosseini.
  • Stewart Han, president of the Terasaki Institute, said, "We are eager to showcase our state-of-the-art facilities and groundbreaking research to the public.
  • The Terasaki Institute also has administrative and research and development facilities located in Westwood and West Los Angeles.

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Retrieved on: 
Monday, April 3, 2023
GMP, Institute of Health and Biomedical Innovation, CSE, Research, Revive, RVV, Therapy, Mental health, IND, MDMA, Pharmaceutical industry

TORONTO, April 03, 2023 (GLOBE NEWSWIRE) --  Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty pharmaceutical company, is pleased to announce the initiation of the research and development of its novel transdermal microneedle patch to deliver 3,4-Methylenedioxy​methamphetamine (“MDMA”) (“MDMA patch”). Following the exclusive supply agreement with PharmaAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) to obtain PharmAla’s LaNeo, GMP source of MDMA, the Company has purchased MDMA supply to support upcoming IND-enabling studies with the MDMA patch.

Key Points: 
  • TORONTO, April 03, 2023 (GLOBE NEWSWIRE) --  Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty pharmaceutical company, is pleased to announce the initiation of the research and development of its novel transdermal microneedle patch to deliver 3,4-Methylenedioxy​methamphetamine (“MDMA”) (“MDMA patch”).
  • Following the exclusive supply agreement with PharmaAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) to obtain PharmAla’s LaNeo, GMP source of MDMA, the Company has purchased MDMA supply to support upcoming IND-enabling studies with the MDMA patch.
  • Recently, Revive Therapeutics announced it entered into a research collaboration agreement with PharmaTher Holdings (CSE: PHRM) (OTCQB: PHRRF) to evaluate their microneedle patch technology with MDMA.
  • PharmaTher has completed a non-clinical research study with Terasaki Institute for Biomedical Innovation (TIBI) evaluating the delivery of its MDMA patch.

Chad A. Mirkin to Receive 2023 Paul Terasaki Innovation Award

Retrieved on: 
Tuesday, February 21, 2023
DNA, Memory, SNA, Institute of Health and Biomedical Innovation, Nanoparticle, RNA, Research, Student, Education, Medical device, Northwestern University

LOS ANGELES, Feb. 21, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce Professor Chad A. Mirkin of Northwestern University as the recipient of their 2023 Paul Terasaki Innovation Award.

Key Points: 
  • LOS ANGELES, Feb. 21, 2023 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) is pleased to announce Professor Chad A. Mirkin of Northwestern University as the recipient of their 2023 Paul Terasaki Innovation Award.
  • The award will be presented at TIBI's inaugural Terasaki Innovation Summit, to be held March 8-10, 2023, at the UCLA Meyer & Renee Luskin Center.
  • The award was created in memory of Dr. Paul I. Terasaki, a pioneer in the field of organ transplant research and innovation, who established the original Terasaki Institute.
  • "Professor Mirkin embodies the very essence of what we would like to recognize with the Paul Terasaki Innovation Award," said Ali Khademhosseini, TIBI's Director and CEO.